In case you missed it: November 22 to 26
It was a very busy week for the Contemporary Pediatrics team.
This week’s top articles included:
FDA OKs treatment for kids with achondroplasia
The US Food and Drug Administration (FDA) has approved VOXZOGO™ (vosoritide) for use in children aged 5 years and older who have open growth plates and achondroplasia.
Help parents prepare a “pandemic first aid kit”
Many parents have a typical first aid kit with Band-Aids® and a thermometer. Helping them build a "pandemic first aid kit" can help clinicians with evaluation during virtual visits and prevent unnecessary visits to urgent care or the emergency department.
Trial examines safety and efficacy of HPV vaccine in young cancer survivors
Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.
All about vaccines: Updates for pediatric nurse practitioners
The November issue covered a variety of topics on vaccination, which can help clinicians have candid conversations with colleagues, patients, and families.
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Study finds reduced CIN3+ risk from early HPV vaccination
April 17th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
